Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Datroway (datopotamab deruxtecan) has been given the green light in the EU as a treatment for patients ... to market by AZ and Daiichi Sankyo after Enhertu (trastuzumab deruxtecan), a HER2 ...